2022
Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis
Kerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, PMCID: PMC11472026, DOI: 10.1111/trf.17136.Peer-Reviewed Original ResearchConceptsAcinetobacter calcoaceticus-baumannii complexBlood productsS. saprophyticusPlatelet unitsContaminated blood productsCDC investigationsApheresis platelet productsTransfusion reactionsPolymicrobial contaminationPlatelet productsDisease controlBacterial isolatesStudy designStaphylococcus saprophyticusPolymicrobial interactionsCDC casesSaprophyticusFuture studiesPotential interactionsCommon sourceSepsisIsolatesCasesCoaggregationCan transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Rodriguez JV, Tormey CA. Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone? Transfusion And Apheresis Science 2022, 61: 103402. PMID: 35288056, DOI: 10.1016/j.transci.2022.103402.Peer-Reviewed Original ResearchConceptsTransfusion-associated graftTA-GVHDHost diseaseCellular blood productsHigh mortality rateWhite blood cellsBlood productsEffective treatmentMortality rateTransfusion communityHigh mortalityMedical literatureBlood cellsDiseaseDevastating diseaseGraftLeukocytesLeukoreductionQuantitative reductionHospitalMortality
2021
Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor
Jacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.Peer-Reviewed Original ResearchConceptsCellular therapy productsHematopoietic stem cellsAllogeneic blood productsAutologous hematopoietic stem cellsHematopoietic stem cell productsPathogenic Gram-negative organismsNormal skin floraTherapy productsCase of SalmonellaStem cell productsGram-negative organismsAsymptomatic donorsTherapeutic dilemmaBlood productsPathogen reduction technologySkin floraHSC productsAdverse effectsCell productsPrior reportsSignificant reductionStem cellsSalmonellosisSalmonella bacteriaMost microorganisms
2020
The evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2019
Fatal acute hemolytic transfusion reaction due to anti‐B from a platelet apheresis unit stored in platelet additive solution
Balbuena‐Merle R, West FB, Tormey CA, Hendrickson JE. Fatal acute hemolytic transfusion reaction due to anti‐B from a platelet apheresis unit stored in platelet additive solution. Transfusion 2019, 59: 1911-1915. PMID: 30865314, DOI: 10.1111/trf.15240.Peer-Reviewed Original ResearchConceptsGroup B patientsHemolytic transfusion reactionsDirect antiglobulin testB patientsTransfusion reactionsApheresis unitsBlood group B patientsRelapsed acute myeloid leukemiaAcute hemolytic transfusion reactionAnti-human globulin phaseHigh lactate dehydrogenaseAnti-human globulinAcute myeloid leukemiaRecipient testingDonor testingRecipient variablesExtravascular hemolysisPlatelet transfusionsTransfusion recipientsAntibody screenHigh bilirubinPLT transfusionsAntiglobulin testBlood productsMyeloid leukemiaTransfusion-related red blood cell alloantibodies: induction and consequences
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 2019, 133: 1821-1830. PMID: 30808636, PMCID: PMC6484385, DOI: 10.1182/blood-2018-08-833962.Peer-Reviewed Original ResearchConceptsTransfusion recipientsBlood donorsPreventative strategiesBlood product exposureCompatible RBC unitsRBC alloantibody formationHemolytic transfusion reactionsDevelopment of alloantibodiesAdaptive immune factorsJudicious transfusionRBC alloimmunizationImmunomodulatory therapyAlloantibody formationBlood transfusionRBC alloantibodiesRecipient variablesFuture pregnanciesImmune factorsTransfusion reactionsBlood productsHemolytic diseaseFuture transfusionsHuman studiesTransfusionAlloantibodies
2017
How do we perform and bill for blood bank physician consultative services?
Jhang JS, Francis RO, Winkler A, Tormey C. How do we perform and bill for blood bank physician consultative services? Transfusion 2017, 57: 2311-2318. PMID: 28833250, DOI: 10.1111/trf.14264.Peer-Reviewed Original ResearchConceptsIndividual patientsTertiary care teaching hospitalCurrent Procedural Terminology codesPhysician servicesTransfusion medicine physiciansProcedural Terminology codesHealth care providersComponent therapyProvider educationTransfusion reactionsBlood productsTeaching hospitalClinical significanceInappropriate testingCare providersMedicine physiciansTerminology codesApheresis proceduresPatientsPhysiciansConsultative servicesLaboratory test resultsHealth careMedical servicesMedical direction
2009
Clinical trials for pathogen reduction in transfusion medicine: A review
McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.Peer-Reviewed Original ResearchConceptsClinical trialsBlood productsDonor screening programsDonor blood productsRisk of transmissionInfective donorsTransfusion recipientsScreening programClinical settingInfectious diseasesTransfusion medicineTesting regimensPI treatmentTrialsScreening assaysRiskPathogensPotential toxicityPromising strategyDetection of pathogensRegimensPathogen reductionSensitive methodDiseaseRecipients